A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
To evaluate the efficacy and safety of tacrolimus capsules in patients with myasthenia gravis
 who are inadequately treated by glucocorticoid.
Inclusion Criteria:

 -  diagnosed as myasthenia gravis (MG) by clinical diagnosis

 -  QMG scores ≥7 at the time of enrollment

 -  basic treatment drugs are mainly glucocorticoids, and the efficacy of glucocorticoid
 therapy was not sufficient

 Exclusion Criteria:

 -  receiving blood purification therapy or immunoglobulin therapy within 8 weeks before
 the study

 -  QMG swallowing function score ≥ 2 points or QMG vital capacity = 3

 -  abnormal hepatic functions

 -  uncontrolled diabetes patients

 -  hyperkalemia patients

 -  immuno-inhibitors are forbidden due to malignancy, history of malignancy or history of
 HIV infection

 -  patients who are allergic to Tacrolimus or macrolide antibiotics

 -  receiving other immuno-inhibitors within 12 weeks